地特胰岛素联合格列齐特缓释片治疗2型糖尿病观察(1)
[摘要] 目的 研究地特胰岛素联合格列齐特缓释片治疗2型糖尿病的临床疗效及对肝肾功能的影响。 方法 选择该院2013年3月—2015年8月肾癌患者的临床病例100例进行分析，随机分为观察组和对照组，每组50例。对照组采取常规的治疗，观察组采取地特胰岛素联合格列齐特缓释片口服方式治疗，观察比较两组患者的肝肾功能、治疗期间出血低血糖例数和C肽在餐前餐后波动检测值等。 结果 两组患者的肝肾功能没有明显的变化，差异无统计学意义(P>0.05)；观察组治疗期间出现低血糖的例数明显低于对照组，差异有统计学意义(P<0.05)；C肽检测结果上在治疗前两组组间对比，差异无统计学意义(P>0.05)；治疗后两组都有大幅度上升，观察组上升幅度比对照组大(P<0.05)。结论 地特胰岛素联合格列齐特缓释片治疗可以更好的控制2型糖尿病的病情，治疗安全性高，值得在临床上广泛使用。
[关键词] 2型糖尿病；地特胰岛素；格列齐特缓释片
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2017)05(b)-0009-02
[Abstracts] Objective This paper tries to study the clinical effect of insulin detemir combined with gliclazide sustained-release Tablets for the treatment of type 2 diabetes and its impact on kidney function. Methods 100 cases of renal cell carcinoma from March 2013 to August 2015 in this hospital were analyzed and randomly divided into the observation group and the control group， with 50 cases in each group. The control group received routine treatment， the observation group was received insulin detemir combined with gliclazide sustained-release tablets oral treatment， and then the liver and kidney function， hemorrhage cases of hypoglycemia and C peptide fluctuation detection value before and after meals of the two groups were observed and compared. Results The liver and kidney function of two groups did not change obviously， the difference was not statistically significant(P>0.05)； the number of cases of hypoglycemia in the observation group was significantly lower than the control group during the treatment， the difference was statistically significant(P<0.05)； C peptide test results before and after meals of the two groups were compared， the difference was not statistically significant(P>0.05)； but the value increased in the two groups after treatment， and the observation group increased significantly more than the control group(P<0.05). Conclusion Insulin detemir combined with gliclazide sustained-release tablets for the treatment of type 2 diabetes can better control the disease with high safety， so it is worth clinical application.
[Key words] Type 2 diabetes mellitus； Insulin detemir； Gliclazide sustained-release tablets
2型糖尿病患者的胰島功能严重下降，若只是口服简单的降糖药物不能很好的控制血糖和稳定病情。地特胰岛素是一种长效胰岛素，该药对患者造成低血糖的几率很低，有平稳降血糖的优势[1]。该文选取2013年3月—2015年8月收治的100例患者为研究对象，采用对比方式研究了地特胰岛素联合格列齐特缓释片对2型糖尿病患者的病情的控制效果，详细汇报如下。
1 资料与方法
1.1 一般资料
选取该院收治的2型糖尿病患者病例100例作为研究对象。所有患者经过检查后确诊为2型糖尿病。将100位患者随机分为观察组和对照组，每组50例。观察组有28例男性，22例女性；年龄24～62岁，平均年龄为(42.9±7.1)岁。对照组有21例男性，29例女性；年龄22～59岁，平均年龄为(42.3±7.4)岁。这两组中的所有患者在性别、年龄和其他相关的因素经过统计学分析，差异无统计学意义(P>0.05)。, http://www.100md.com(张丽娜 冯文静 张玉好)
[关键词] 2型糖尿病；地特胰岛素；格列齐特缓释片
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2017)05(b)-0009-02
[Abstracts] Objective This paper tries to study the clinical effect of insulin detemir combined with gliclazide sustained-release Tablets for the treatment of type 2 diabetes and its impact on kidney function. Methods 100 cases of renal cell carcinoma from March 2013 to August 2015 in this hospital were analyzed and randomly divided into the observation group and the control group， with 50 cases in each group. The control group received routine treatment， the observation group was received insulin detemir combined with gliclazide sustained-release tablets oral treatment， and then the liver and kidney function， hemorrhage cases of hypoglycemia and C peptide fluctuation detection value before and after meals of the two groups were observed and compared. Results The liver and kidney function of two groups did not change obviously， the difference was not statistically significant(P>0.05)； the number of cases of hypoglycemia in the observation group was significantly lower than the control group during the treatment， the difference was statistically significant(P<0.05)； C peptide test results before and after meals of the two groups were compared， the difference was not statistically significant(P>0.05)； but the value increased in the two groups after treatment， and the observation group increased significantly more than the control group(P<0.05). Conclusion Insulin detemir combined with gliclazide sustained-release tablets for the treatment of type 2 diabetes can better control the disease with high safety， so it is worth clinical application.
[Key words] Type 2 diabetes mellitus； Insulin detemir； Gliclazide sustained-release tablets
2型糖尿病患者的胰島功能严重下降，若只是口服简单的降糖药物不能很好的控制血糖和稳定病情。地特胰岛素是一种长效胰岛素，该药对患者造成低血糖的几率很低，有平稳降血糖的优势[1]。该文选取2013年3月—2015年8月收治的100例患者为研究对象，采用对比方式研究了地特胰岛素联合格列齐特缓释片对2型糖尿病患者的病情的控制效果，详细汇报如下。
1 资料与方法
1.1 一般资料
选取该院收治的2型糖尿病患者病例100例作为研究对象。所有患者经过检查后确诊为2型糖尿病。将100位患者随机分为观察组和对照组，每组50例。观察组有28例男性，22例女性；年龄24～62岁，平均年龄为(42.9±7.1)岁。对照组有21例男性，29例女性；年龄22～59岁，平均年龄为(42.3±7.4)岁。这两组中的所有患者在性别、年龄和其他相关的因素经过统计学分析，差异无统计学意义(P>0.05)。, http://www.100md.com(张丽娜 冯文静 张玉好)